Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Inherited mutations in CHEK2 (Checkpoint Kinase 2) are associated with up to 48% lifetime risk of breast cancer in women, and may also increase risk of breast cancer and prostate cancer in men, as well as colon cancer in both men and women. Some research suggests that certain CHEK2 mutations may be associated with increased risk of other cancers. Research into the types cancers and exact cancer risk associated with inherited mutations in CHEK2 is ongoing.
National guidelines recommend that women with CHEK2 mutations undergo increased screening for breast cancer beginning at age 40. Other options, including participating in research studies, may be available to manage risk. We recommend consulting with a genetics expert who can assess your personal and family history of cancer, and can help you to determine the best risk-management plan.